Curiously, this is both good news and bad news for Novo Nordisk stock. On the good news front, it stands to reason that if Ozempic is already a popular product ... it's to make the most of ...

Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...

A new generation of GLP-1 drugs promising fast results continues to rock the weight loss industry, which has emphasized ...

One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for just $60 each, and as recently as last July, traded in the mid-140s. Novo ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

Novo Nordisk (NYSE:NVO) specializes in the research, development, production, and distribution of pharmaceutical products ... the beginning of 2025, while popular AI stocks lost around 25%.

The US Food and Drug Administration seized fake Ozempic injections. This happened on April 9, 2025. Novo Nordisk warned about ...